Andere Kunden interessierten sich auch für
![Formulation and In Vitro Evaluation of Buccal Tablet of Famotidine]( "Formulation and In Vitro Evaluation of Buccal Tablet of Famotidine")
Formulation and In Vitro Evaluation of Buccal Tablet of Famotidine38,99 €![Formulation and In-vitro Evaluation of Alfuzosin HCl Floating Tablet]( "Formulation and In-vitro Evaluation of Alfuzosin HCl Floating Tablet")
Formulation and In-vitro Evaluation of Alfuzosin HCl Floating Tablet40,99 €![Formulation & In-Vitro Evaluation of Tolperisone HCl Buoyant Tablet]( "Formulation & In-Vitro Evaluation of Tolperisone HCl Buoyant Tablet")
Formulation & In-Vitro Evaluation of Tolperisone HCl Buoyant Tablet40,99 €![Formulation of Fast Dispersible Tablet of Fexofenadine HCl]( "Formulation of Fast Dispersible Tablet of Fexofenadine HCl")
Formulation of Fast Dispersible Tablet of Fexofenadine HCl38,99 €![Mucoadhesive Bilayer Lidocaine Buccal Tablet to Treat Gum Diseases]( "Mucoadhesive Bilayer Lidocaine Buccal Tablet to Treat Gum Diseases")
Mucoadhesive Bilayer Lidocaine Buccal Tablet to Treat Gum Diseases38,99 €![Formulation,Evaluation of Miconazole Nitrate & Ibuprofen Buccal Tablet]( "Formulation,Evaluation of Miconazole Nitrate & Ibuprofen Buccal Tablet")
Formulation,Evaluation of Miconazole Nitrate & Ibuprofen Buccal Tablet38,99 €![Formulation and Evaluation of Mucoadhesive buccal Patches of Labetalol]( "Formulation and Evaluation of Mucoadhesive buccal Patches of Labetalol")
Formulation and Evaluation of Mucoadhesive buccal Patches of Labetalol32,99 €
Venlafaxine Hydrochloride is an oral antidepressant agent of the Serotonin-Norepinephrine Reuptake Inhibitor class. Venlafaxine Hydrochloride has been studied for the treatment of panic disorder, post-traumatic stress disorder, and the treatment of hot flashes in patients who cannot or do not want to take hormone replacement therapy. The dose of Venlafaxine hydrochloride ranges from 75 to 225 mg three times a day and it undergoes extensive first pass metabolism hence it has only 45% bioavaibility. The short half life of the drug 5 hr indicates the need for modified release dosage form. Venlafaxine HCl was chosen as model drug with an aim to developed mucoadhesive buccal tablet that minimize dose related side effects and reducing the dosing frequency of drug and finally improve the bioavaibility.